MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'exelon'. Sat, 03 Sep 2011 02:21:33 +0100 http://www.medworm.com/index.php?rid=3448841&cid=t_136749_87_f&fid=36438&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FCato-at-liberty%2F%7E3%2FcXWA7doTgeo%2F By Jerry TaylorLast week I was on John Stossel’s (most excellent) new show on Fox Business News to discuss energy policy — in particular, popular myths that Republicans have about energy markets.  One of the topics I touched upon was nuclear power.  My argument was the same that I have offered in print: Nuclear power is a swell technology but, given the high construction costs associated with building nuclear reactors, it’s a technology that cannot compete in free markets without a massive amount of government support.  If one believes in free markets, then one should look askance at such policies.  As expected, the atomic cult has taken offense.  Now, it is reasonable to argue that excessive regulatory oversight has driven up the cost of nuclear power and that a “betterâ€... Cato-at-liberty blogs http://www.medworm.com/rss/comments.php?id=3448841 Thu, 08 Apr 2010 00:36:48 +0100 3448841 http://www.medworm.com/index.php?rid=2442629&cid=t_136749_137_f&fid=35426&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FTheAlzheimersReadingRoom%2F%7E3%2FFEvYRAzJkrc%2Fside-effects-of-alzheimers-and-dementia.html This study does not suggest that dementia patients shouldn't take these drugs," says Dr. Gill. "What's critical is that patients, caregivers and physicians be aware of the potential side effects, and weigh these risks carefully against the potential for beneficial effects."To receive more information about Alzheimer's -- Subscribe to The Alzheimer's Reading RoomDementia drugs may put some patients at risk, Queen’s study showsSide effects associated with several commonly-prescribed dementia drugs may be putting elderly Canadians at risk, says Queen's University Geriatrics professor Sudeep Gill.Cholinesterase inhibitors (Aricept, Exelon and Reminyl) are often prescribed for people with Alzheimer's disease and related dementias because they increase the level of a chemical in the brain that... Alzheimer's Reading Room, The blogs http://www.medworm.com/rss/comments.php?id=2442629 Sat, 30 May 2009 00:14:42 +0100 2442629 http://www.medworm.com/index.php?rid=1895043&cid=t_136749_131_f&fid=34989&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FGeneticsHealth%2F%7E3%2Fq27N3Quhfbc%2F Medications that have been slowing the mental decline in Alzheimer’s patients are showing promise as drugs that can boost the mental skills of children with Down Syndrome. Two of those promising drugs are Aricept and Exelon, which were found to increase skill levels of Down syndrome children in small clinical trials. Aricept and Exelon are FDA-approved drugs for treating Alzheimer’s. Doctors had observed that adults with Down Syndrome were developing Alzheimer’s disease at an earlier age than the general population. The drugs were given to children, in appropriate doses, to test if they could delay the development of the illness. The results surprised the physicians. In a very short period of time, the children’s communication skills and understanding improved. Dr... Genetics and Health blogs http://www.medworm.com/rss/comments.php?id=1895043 Wed, 22 Oct 2008 08:24:32 +0100 1895043 http://www.medworm.com/index.php?rid=1449314&cid=t_136749_109_f&fid=34788&url=http%3A%2F%2Firvingpsychiatrist.blogspot.com%2F2008%2F05%2Fconsistent-with-report-of-vogels-et-al.html Consistent with the report of Vogels et al., 1997, I have seen a patient's hepatic encephalopathy ameliorated by Namenda 5 mg a day. Where the patient can't take meds orally the cholinesterse inhibitor approach, supported by the experiment of Kabatnik et al., might be tried with an Exelon patch. (Source: a psychiatrist who learned from veterans) a psychiatrist who learned from veterans blogs http://www.medworm.com/rss/comments.php?id=1449314 Sat, 17 May 2008 03:27:00 +0100 1449314 http://www.medworm.com/index.php?rid=1104494&cid=t_136749_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F202510075%2F And so another day comes to an end. We apologize for the late sign off, but sundry errands prevented us from following the usual routine. Nonetheless, we would like to leave you with a few interesting tidbits before you turn in or turn on, as the case may be. See you in the morning… Lilly Will Seek FDA Approval For Zyprexa Injections (Bloomberg News) Investment Firm Sues Abbott Over Discontinued Stent (Yahoo/Reuters) Novarits Awards $25M Exelon Account To Deutsch (Advertising Age) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1104494 Wed, 19 Dec 2007 02:51:57 +0100 1104494 http://www.medworm.com/index.php?rid=1079763&cid=t_136749_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F196817239%2Fwatson_and_novartis_settle_law.html CORONA, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis") on outstanding patent litigation related to Watson's generic version of Exelon(R) (rivastigmine tartrate) capsules.Under the terms of the settlement agreement, Novartis has granted Watson a license to its U.S. patents covering Exelon(R) for a generic version of Exelon(R). The agreement generally provides that Watson will not commence marketing its generic equivalent product until sometime prior to the expiration of the patents covering ... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=1079763 Fri, 07 Dec 2007 17:00:59 +0100 1079763 http://www.medworm.com/index.php?rid=1076928&cid=t_136749_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F196612379%2F And so the time is near - the end of the work week is nearing. Still, much remains to be done - deadlines, meetings, dreaming up new schemes. We can relate. To help you stay fresh, here are a few of the latest missives from afar…. Amgen And FDA Discuss Label Changes For Anemia Drugs (Yahoo/Reuters) Ranbaxy Gets Tentative FDA Approval To Sell Aricept (Bloomberg News) Ipsen And Medicis File To Compete With Botox In The US (PharmaTimes) European Trade Group Pledges To Focus On Kids Meds (The Financial Times) Watson And Novartis Settle Exelon Patent Suit (Yahoo/AP) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1076928 Fri, 07 Dec 2007 12:23:43 +0100 1076928 http://www.medworm.com/index.php?rid=912196&cid=t_136749_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F162312056%2F This is good news for the drugmaker, which is still struggling to gain FDA approval for the pill. Although the EU backing is hardly a surprise. The European Medicines Agency last July indicated the med can be used in combination with other Type 2 diabetes treatments, such as metformin, and EU approval usually occurs within three months. So this endorsement is right on time. (Here’s the Novartis statement). Novartis is counting on Galvus, which some analysts say may generate $1 billion in annual sales, to compensate fo patent losses on older products such as the Lamisil antifungal. An ongoing delay in approval in the US has put Novartis far behind Merck and its Januvia pill, which is generating considerable prescription volume. Both drugs are part of a new class of diabetes meds known... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=912196 Fri, 28 Sep 2007 11:29:42 +0100 912196 http://www.medworm.com/index.php?rid=894335&cid=t_136749_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F160564679%2F And so we all return from the weekend. Hope yours was enjoyable. Ours was splendid. We managed to mow the lawn yesterday, a rare event that met with the approval of the neighbors (not that we care all that much). And we took the shortest of the short people on a hayride to pick a few pumpkins. Now, though, we are again scouring the world for interesting insights. Here are a few of the latest… EU Delays Schering-Plough, Organon Review For Two Weeks (CNNMoney/Dow Jones) EU Approves Pfizer’s Selzentry AIDS Drug (Yahoo/Reuters) Glaxo Wins EU Approval To Sell Cervarix HPV Vaccine (Bloomberg News) Novartis’ Exelon Alzheimer’s Patch Approved By EU (CNN/Thomson Financial) Lilly Sues Sun Pharma To Block Generic Version Of Strattera (Bloomberg News) FDA Delays Approval Of Gla... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=894335 Mon, 24 Sep 2007 11:10:00 +0100 894335 http://www.medworm.com/index.php?rid=894215&cid=t_136749_122_f&fid=35055&url=http%3A%2F%2Fsarasotaneurology.com%2F2007%2F09%2F24%2Ffda-approves-new-alzheimers-medication-patch%2F The FDA has recently approved the dementia fighting drug Exelon in a patch form. The new formulation, Transdermal Exelon, offers patients a new and unique way to get medication which can help with improving cognitive function and slow down memory loss in patients suffering from Alzheimer’s disease. The new patch is also FDA approved for patients with Parkinson associated dementia. This is the second patch approved for use in treatment of Parkinson disease. The other is Neupro, a transdermal patch containing the dopamine agonist rotigotine. Transdermal Exelon joins the group of other medications used to treat Alzheimer’s disease, such as Aricept, Razadyne and Namenda. The patch for of Exelon offers the advantage of not having to take a pill twice daily, continuous medication adm... Sarasota Neurology blogs http://www.medworm.com/rss/comments.php?id=894215 Mon, 24 Sep 2007 11:04:16 +0100 894215 http://www.medworm.com/index.php?rid=800177&cid=t_136749_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F144373788%2F The drugmaker received a warning letter that a professional file card, which is basically promotional material, overestimated the effectiveness of its Alzheimer’s med, contained misleading info concerning risks and unsubstantiated superiority claims, and recommended an unapproved combo with another drug. You can look at the file card here. “These violations are concerning from a public health perspective because they suggest that Exelon is safer or more effective than has been demonstrated, and they encourage the use of Exelon in circumstances other than those for which the drug has been shown to be safe and effective,” wrote Tom Abrams, who heads the FDA’s Division of Drug Marketing, Advertising and Communications, in the letter to Alex Gorsky, who heads Novartis p... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=800177 Wed, 15 Aug 2007 12:06:26 +0100 800177